M Stanley Reduces Revenue and NP Projections for HENGRUI PHARMA (01276.HK), Raises Target Price to $92
Revenue Forecast Adjustment: Morgan Stanley has lowered its total revenue forecasts for HENGRUI PHARMA for 2025-2027 by 2.1%, 3.7%, and 1.8% due to decreased commercial development income from GlaxoSmithKline assets and a decline in the generic drug business.
Net Profit Forecast Reduction: The broker also reduced its net profit forecasts for the same period by 7.4%, 8.9%, and 6.5%, although this was partially offset by higher forecasts for innovative drug sales.
Target Price Increase: Despite the lowered forecasts, Morgan Stanley raised its target price for HENGRUI PHARMA from $86 to $92, maintaining an Overweight rating.
Market Activity: The stock experienced a short selling of $25.50 million, with a short selling ratio of 25.531%.
Trade with 70% Backtested Accuracy
Analyst Views on 01276
About the author
JD's Shen Jianguang: Rapid Growth of AI Infrastructure Enhances Hong Kong's Competitive Advantage
Hong Kong's AI Development Environment: Hong Kong is recognized as a vibrant and internationalized hub for AI companies, facilitating business expansion and innovation, according to Shen Jianguang, Vice President and Chief Economist of JD-SW.
Strategic Advantages in AI: The city is expected to leverage its rapid AI infrastructure development to enhance its position in data science, fintech, and intelligent manufacturing, serving as a bridge between mainland China and global markets.
Biomedical Technology Cooperation: Dai Hongbin, Vice Chairman of HENGRUI PHARMA, emphasized the importance of Hong Kong's strategic role in the international innovation ecosystem and expressed interest in collaborating with the Office for Attracting Strategic Enterprises to advance biomedical technology.
Market Activity: The article notes current short selling statistics for Hong Kong stocks, indicating significant market activity, with specific figures for JD-SW and HENGRUI PHARMA.
M Stanley Reduces Revenue and NP Projections for HENGRUI PHARMA (01276.HK), Raises Target Price to $92
Revenue Forecast Adjustment: Morgan Stanley has lowered its total revenue forecasts for HENGRUI PHARMA for 2025-2027 by 2.1%, 3.7%, and 1.8% due to decreased commercial development income from GlaxoSmithKline assets and a decline in the generic drug business.
Net Profit Forecast Reduction: The broker also reduced its net profit forecasts for the same period by 7.4%, 8.9%, and 6.5%, although this was partially offset by higher forecasts for innovative drug sales.
Target Price Increase: Despite the lowered forecasts, Morgan Stanley raised its target price for HENGRUI PHARMA from $86 to $92, maintaining an Overweight rating.
Market Activity: The stock experienced a short selling of $25.50 million, with a short selling ratio of 25.531%.
